Back to search results

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Abroad (travel likely)RecruitingPHASE1

Conditions

Melanoma · Unresectable Solid Tumors · Neoplasms · Neoplasms by Histologic Type · Neoplasms by Site · Antineoplastic Agents, Immunological · Antineoplastic Agents · Immune Checkpoint Inhibitors · Molecular Mechanisms of Pharmacological Action · Nivolumab

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Chicago Medical Center, Chicago, Illinois, United States

    Contact: Study coordinator (Robyn Hseu, RN) · rdeneau1@bsd.uchicago.edu
    Contact: Principal Investigator (Steven Chmura, MD)

  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

    Contact: Study coordinator (Danielle L Bednarz, BSN) · bednarzdl@upmc.edu · 412-623-1191
    Contact: Study coordinator (Amy L Rose, BSN) · kennaj@upmc.edu · 412-647-8587
    Contact: Principal Investigator (Yana Najjar, MD, FACP)
Study leads

  • Yana Najjar, MD, FACP

    Principal Investigator

    UPMC Hillman Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)